IL281409A - Musk inhibition - Google Patents

Musk inhibition

Info

Publication number
IL281409A
IL281409A IL281409A IL28140921A IL281409A IL 281409 A IL281409 A IL 281409A IL 281409 A IL281409 A IL 281409A IL 28140921 A IL28140921 A IL 28140921A IL 281409 A IL281409 A IL 281409A
Authority
IL
Israel
Prior art keywords
musk
inhibition
Prior art date
Application number
IL281409A
Other languages
English (en)
Hebrew (he)
Inventor
Maria Van Der Maarel Silvere
Justus Gerard Maria Verschuuren Johannes
Gerardina Maria Huijbers Martina
Jan Plomp Jakob
Original Assignee
Academisch Ziekenhuis Leiden
Maria Van Der Maarel Silvere
Justus Gerard Maria Verschuuren Johannes
Gerardina Maria Huijbers Martina
Jan Plomp Jakob
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NL2021589A external-priority patent/NL2021589B1/en
Application filed by Academisch Ziekenhuis Leiden, Maria Van Der Maarel Silvere, Justus Gerard Maria Verschuuren Johannes, Gerardina Maria Huijbers Martina, Jan Plomp Jakob filed Critical Academisch Ziekenhuis Leiden
Publication of IL281409A publication Critical patent/IL281409A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL281409A 2018-09-10 2021-03-10 Musk inhibition IL281409A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2021589A NL2021589B1 (en) 2018-09-10 2018-09-10 MuSK inhibition
NL2023119 2019-05-13
PCT/NL2019/050576 WO2020055240A1 (en) 2018-09-10 2019-09-05 Musk inhibition

Publications (1)

Publication Number Publication Date
IL281409A true IL281409A (en) 2021-04-29

Family

ID=68138766

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281409A IL281409A (en) 2018-09-10 2021-03-10 Musk inhibition

Country Status (8)

Country Link
US (1) US20220002438A1 (https=)
EP (1) EP3850014A1 (https=)
JP (2) JP2022500387A (https=)
CN (1) CN113614112A (https=)
AU (1) AU2019337338A1 (https=)
CA (1) CA3112288A1 (https=)
IL (1) IL281409A (https=)
WO (1) WO2020055240A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114487448B (zh) * 2022-01-21 2022-10-18 天津天海新域生物科技有限公司 用于检测重症肌无力相关抗体的组合物、试剂盒及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5814478A (en) 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
EP1411851B1 (en) 2001-08-03 2006-11-02 Tyco Healthcare Group LP Marker for use with a tissue marking apparatus
US7759314B2 (en) * 2001-08-15 2010-07-20 Brown University Treatment of muscular dystrophies and related disorders
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7807378B2 (en) * 2005-12-29 2010-10-05 Industrial Technology Research Institute (Itri) Method of diagnosing myasthenia gravis and kits therefor
CN101490085A (zh) * 2006-06-12 2009-07-22 特鲁比昂药品公司 具有效应功能的单链多价结合蛋白
JP2011207769A (ja) * 2010-03-29 2011-10-20 Arubion:Kk 化粧料及び皮膚外用剤
JP2014520148A (ja) * 2011-06-20 2014-08-21 セントルイス ユニバーシティ 治療のための神経筋接合部への標的化
WO2013074636A1 (en) * 2011-11-14 2013-05-23 New York University Muscle specific receptor kinase and modulation thereof
WO2015039015A2 (en) * 2013-09-13 2015-03-19 New York University Methods for treating muscle specific receptor kinase myasthenia gravis
JP7023840B2 (ja) * 2015-10-07 2022-02-22 メモリアル スローン ケタリング キャンサー センター 神経筋接合活性のモジュレーターを同定するｉｎ ｖｉｔｒｏの方法

Also Published As

Publication number Publication date
CA3112288A1 (en) 2020-03-19
JP2025016653A (ja) 2025-02-04
EP3850014A1 (en) 2021-07-21
AU2019337338A1 (en) 2021-04-08
US20220002438A1 (en) 2022-01-06
JP2022500387A (ja) 2022-01-04
WO2020055240A1 (en) 2020-03-19
CN113614112A (zh) 2021-11-05

Similar Documents

Publication Publication Date Title
DK4045039T3 (da) Hæmning af human integrin-alfa4beta7
EP3857879A4 (en) COMBINED INTER-INTRA PREDICTION SIMPLIFICATION
IL280782A (en) Inhibiting αv β6 integrin
SI3743406T1 (sl) Modulatorji TMEM16A
EP3801500A4 (en) Inhibitors of sarm1
EP3874764A4 (en) TEXT ANNOTATION OF ACOUSTIC EFFECTS
IL269540A (en) Purification of phycobiliproteins
PT3645518T (pt) Síntese de omecamtiv mecarbil
IL283967A (en) Modulators of hsd17b13 expression
IL281492A (en) Modulators of pnpla3 expression
DK3565542T3 (da) Polymorphic forms of rad1901-2hcl
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
IL280453A (en) Benzene derivative
DK3697947T3 (da) Hensyntagen til inducerede tilpasningseffekter
IL285119A (en) Use of spiropidion
IL281409A (en) Musk inhibition
EP3962486A4 (en) ESCAPEMENT OF USP36
EP3817575C0 (de) Solubilisierung schwerlöslicher kühlsubstanzen
EP3794030A4 (en) INHIBITION OF FOLLISTATIN
ES2743719R1 (es) Nuevas fases solidas de rifaximina
UY4641S (es) Línea de luminarias
UA39602S (uk) Комплект етикеток
UA38661S (uk) Комплект етикеток
UA39416S (uk) Комплект етикеток
DK3720442T3 (da) Inhibering af mutant idh-1